Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CLOVER HEALTH INVESTMENTS, CORP. /DECLOV · Entity 4419 | Director | January 06, 2025 | January 08, 2025 |
| Senior Connect Acquisition Corp. ISNRH · Entity 112401 | Director | December 10, 2020 | December 10, 2020 |
| TIVITY HEALTH, INC.TVTY · Entity 125776 | Director | February 28, 2020 | February 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CLOVER HEALTH INVESTMENTS, CORP. /DE
Report date January 06, 2025 · Filed January 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 598,622 |
Reported balance
After 2025-01-06 transaction · row 1
1 source rowRow 1 · 2025-01-06 · Grant · Acquired 60,975 · Balance 598,622 F1: Represents shares of Class A common stock underlying a time-based restricted stock unit award (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2025, subject to the Reporting Person's continued service as a director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Class A common stock underlying a time-based restricted stock unit award (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2025, subject to the Reporting Person's continued service as a director through such vesting date.
Senior Connect Acquisition Corp. I
Report date December 10, 2020 · Filed December 10, 2020
This filing explicitly reported no securities owned.
TIVITY HEALTH, INC.
Report date February 28, 2020 · Filed February 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,304 |
Reported balance
After 2020-02-28 transaction · row 1
1 source rowRow 1 · 2020-02-28 · Purchase · Acquired 4,065 · Balance 40,304 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Livongo Health, Inc.
Report date September 11, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 12,080 |
Reported balance
After 2020-09-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-09-11 · Other · Acquired 12,080 · Balance 12,080 F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP. F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-29 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-10-29 · Other · Disposed 1,185,097 · Balance 0 F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-29 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-10-29 · Other · Disposed 109,748 · Balance 0 F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-29 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2020-10-29 · Other · Disposed 176,361 · Balance 0 F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-29 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-10-29 · Other · Disposed 195,277 · Balance 0 F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 35,887 |
Reported balance
After 2020-10-30 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2020-10-30 · Other · Disposed 940,788 · Balance 35,887 F13: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners. F14: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 185,121 |
Reported balance
After 2020-10-30 transaction · row 10
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 10 · 2020-10-30 · Other · Acquired 173,041 · Balance 185,121 F16: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP. F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-30 transaction · row 13
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 13 · 2020-10-30 · Disposition to issuer · Disposed 35,887 · Balance 0 F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F14: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-30 transaction · row 14
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 14 · 2020-10-30 · Disposition to issuer · Disposed 185,121 · Balance 0 F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 1,693,023 |
Reported balance
After 2020-10-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-10-16 · Gift · Disposed 135,000 · Balance 1,693,023 |
| Common StockSEC Table I · non-derivative | Direct | 1,718,701 |
Reported balance
After 2020-10-29 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2020-10-29 · Other · Acquired 25,468 · Balance 1,718,701 F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E. F12: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 1,745,807 |
Reported balance
After 2020-10-30 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2020-10-30 · Other · Acquired 27,106 · Balance 1,745,807 F15: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P. |
| Common StockSEC Table I · non-derivative | Direct | 1,743,319 |
Reported balance
After 2020-10-30 transaction · row 11
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 11 · 2020-10-30 · Disposition to issuer · Disposed 2,488 · Balance 1,743,319 F17: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 12
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 12 · 2020-10-30 · Disposition to issuer · Disposed 1,743,319 · Balance 0 F18: Includes 763,507 RSUs. F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F20: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F21: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP.
F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners.
F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners.
F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners.
F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners.
F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E.
F12: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020.
F13: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners.
F14: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F15: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P.
F16: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP.
F17: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer.
F18: Includes 763,507 RSUs.
F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).
F20: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).
F21: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
Medidata Solutions, Inc.
Report date October 28, 2019 · Filed October 28, 2019
Section 16 reporting ended · disclosed 2019-10-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-28 transaction · row 1
1 source rowRow 1 · 2019-10-28 · Disposition to issuer · Disposed 28,827 · Balance 0 F1: On October 28, 2019, pursuant to the Agreement and Plan of Merger, dated as of June 11, 2019, by and among Dassault Systemes SE ("DS"), Dassault Systemes Americas Corp., a Delaware corporation ("Parent"), 3DS Acquisition 6 Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and Medidata Solutions, Inc., a Delaware corporation (the "Issuer"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent and an indirect wholly-owned subsidiary of DS (the "Merger"). F2: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2021-05-31 | Direct | 0 |
Reported balance
After 2019-10-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-28 · Disposition to issuer · Disposed 4,494 · Balance 0 F3: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option. F4: These options are fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2022-05-16 | Direct | 0 |
Reported balance
After 2019-10-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-28 · Disposition to issuer · Disposed 5,214 · Balance 0 F3: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option. F4: These options are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 28, 2019, pursuant to the Agreement and Plan of Merger, dated as of June 11, 2019, by and among Dassault Systemes SE ("DS"), Dassault Systemes Americas Corp., a Delaware corporation ("Parent"), 3DS Acquisition 6 Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and Medidata Solutions, Inc., a Delaware corporation (the "Issuer"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent and an indirect wholly-owned subsidiary of DS (the "Merger").
F2: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration").
F3: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.
F4: These options are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2025 Filed Jan 8, 2025 16:33 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantClass A Common Stock | 60,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001801170-25-000015 · wk-form4_1736371994.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 598,622 F1 · shares: Represents shares of Class A common stock underlying a time-based restricted stock unit award (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2025, subject to the Reporting Person's continued service as a director through such vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 16:23 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantClass A Common Stock | 206,185 | $0.97 | $199,999.45 |
DisclosureSEC source: 0001801170-24-000026 · wk-form4_1704489768.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 537,647 F1 · shares: Represents shares of Class A common stock underlying a time-based restricted stock unit award (RSUs). The RSUs will vest in full on the first anniversary of January 3, 2024, subject to the Reporting Person's continued service as a director through such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:35 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantClass A Common Stock | 176,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000468 · wf-form4_167295450617790.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,462 F1 · shares: Represents shares of Class A common stock of Clover Health Investments, Corp. (the "Company") underlying a time-based restricted stock unit award ("RSUs"). The RSUs will vest in full on the first anniversary of January 3, 2023, subject to the Reporting Person's continued service as a member of the Company's Board of Directors through such vesting date. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 18:00 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionRestricted Stock Unit · Derivative | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025505 · wf-form4_166422960816234.xml · derivative · entry 3 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 27,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · shares: The remaining number of the shares subject to the RSU award vested on the date of the 2022 Annual Meeting. F3 · derivative.exercise_date: The remaining number of the shares subject to the RSU award vested on the date of the 2022 Annual Meeting. F3 · derivative.expiration_date: The remaining number of the shares subject to the RSU award vested on the date of the 2022 Annual Meeting. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 18:00 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantClass A Common Stock | 20,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025505 · wf-form4_166422960816234.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,471 F2 · shares: Represents shares of Class A common stock underlying a time-based RSU. One hundred percent of the RSUs will vest on the first anniversary of the Date of Grant, subject to the Reporting Person's continued service as a member of the Company's Board of Directors through such date. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 18:00 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass A Common Stock | 27,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025505 · wf-form4_166422960816234.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 08:03 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | PurchaseClass A Common Stock | 80,000 | $3.10 | $248,072.00 |
DisclosureSEC source: 0001628280-22-006156 · wf-form4_164734580175403.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,100 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.085 to $3.14 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:22 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionRestricted Stock Unit · Derivative | 27,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000724 · wf-form4_164195413048020.xml · derivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,100 Underlying: Class A Common Stock · 27,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vested as to 50% of the shares subject to the award on January 7, 2022, and will vest as to the remaining shares subject to the award on the date of the 2022 Annual Meeting, subject to the Reporting Person's continued service as a member of the Board through such vesting date. F2 · derivative.expiration_date: The RSUs vested as to 50% of the shares subject to the award on January 7, 2022, and will vest as to the remaining shares subject to the award on the date of the 2022 Annual Meeting, subject to the Reporting Person's continued service as a member of the Board through such vesting date. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:22 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | Exercise / conversionClass A Common Stock | 27,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000724 · wf-form4_164195413048020.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 12:43 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | GrantRestricted Stock Unit · Derivative | 54,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025578 · doc4.xml · derivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,200 Underlying: Class A Common Stock · 54,200 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest as to 50% of the shares subject to the award on the first anniversary of January 7, 2021, and will vest as to the remaining shares subject to the award on the date of the 2022 Annual Meeting, subject to the Reporting Person's continued service as a member of the Board through each such vesting date. F2 · derivative.expiration_date: The RSUs will vest as to 50% of the shares subject to the award on the first anniversary of January 7, 2021, and will vest as to the remaining shares subject to the award on the date of the 2022 Annual Meeting, subject to the Reporting Person's continued service as a member of the Board through each such vesting date. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerCommon Stock | 185,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 14 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F19 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F2 · ownership.nature: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerCommon Stock | 35,887 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 13 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F19 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F14 · ownership.nature: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerCommon Stock | 1,743,319 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 12 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F18 · shares: Includes 763,507 RSUs. F19 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F20 · price: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F21 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerCommon Stock | 2,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 11 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,743,319 F17 · shares: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 173,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 10 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 185,121 F16 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP. F2 · ownership.nature: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 27,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 9 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,745,807 F15 · kind: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 940,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 8 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 35,887 F13 · kind: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners. F14 · ownership.nature: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 25,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 7 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,718,701 F11 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E. F12 · balance_after: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 195,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 6 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F9 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F10 · ownership.nature: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 176,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 5 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F8 · ownership.nature: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 109,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 4 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F5 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F6 · ownership.nature: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 1,185,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 3 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F4 · ownership.nature: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | GiftCommon Stock | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,693,023 Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 18:15 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 23 | $124.46 | $2,862.58 |
DisclosureSEC source: 0001209191-20-050762 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 976,675 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.46 to $124.465, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by 7wire Ventures Fund, L.P., or 7wire LP. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 17,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050490 · doc4.xml · nonDerivative · entry 6 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,828,023 F11 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire LP, 7wire Ventures, LLC - Series Livongo D and 7wire Ventures, LLC - Series Livongo E. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 312,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050490 · doc4.xml · nonDerivative · entry 5 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 976,698 F9 · kind: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P., or 7wire LP, without consideration to its partners. F10 · ownership.nature: The shares are held of record by 7wire LP. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 65,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050490 · doc4.xml · nonDerivative · entry 4 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 195,277 F7 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F8 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 58,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050490 · doc4.xml · nonDerivative · entry 3 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 176,361 F5 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F6 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 36,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050490 · doc4.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 109,748 F3 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F4 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 395,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050490 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,185,097 F1 · kind: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F2 · ownership.nature: The shares are held of record by 7wire Ventures LLC-Series EosHealth. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Ventures LLC-Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 11, 2020 Filed Oct 30, 2020 17:20 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 12,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001639225-20-000063 · wf-form4_160409282066773.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 12,080 F1 · kind: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP. F2 · ownership.nature: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 21:12 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 84,132 | $124.50 | $10,474,434.00 |
DisclosureSEC source: 0001209191-20-049681 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,810,499 F1 · kind: On August 5, 2020, the Issuer entered into an Agreement and Plan of Merger with Teladoc Health, Inc. ("Teladoc") and Tempranillo Merger Sub, Inc., a wholly-owned subsidiary of Teladoc ("Merger Sub"), pursuant to which Merger Sub will merge with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Teladoc (the "Merger"). Pursuant to the terms of the Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2020 (the "Trading Plan"), all sales pursuant to the Trading Plan were automatically suspended following the public announcement of the Merger without any action by the reporting person, and the Trading Plan was subsequently terminated. The number of shares sold and reported on this form is consistent with the number of shares that would have been sold by the reporting person pursuant to the Trading Plan had the Trading Plan not been suspended in connection with the Merger. F2 · kind: In addition, in connection with the Merger the reporting person entered into a voting agreement with Teladoc and certain other stockholders of the Issuer party thereto (the "Voting Agreement"), pursuant to which, subject to certain exceptions, the reporting person agreed to vote all shares of the Issuer's common stock held by the reporting person in favor of the approval of the Merger. The sales reported on this form are expressly permitted and contemplated by the Voting Agreement, which permits the reporting person to sell or transfer a number of shares of the Issuer's common stock equivalent to such number of shares that would have been sold had the Trading Plan remained in effect. Following the sales reported on this form, the reporting person continues to hold over 85% of the shares of the Issuer's common stock directly held immediately prior to such sales. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 16:17 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 5,734 | $132.53 | $759,927.02 |
DisclosureSEC source: 0001209191-20-048623 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,894,631 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 446 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on May 15, 2020. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 17:23 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 48,565 | $113.83 | $5,528,153.95 |
DisclosureSEC source: 0001209191-20-043339 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,899,919 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 19:34 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 52 | $74.76 | $3,887.52 |
DisclosureSEC source: 0001209191-20-039946 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,289,209 F1 · ownership.nature: The shares are held of record by 7wire Ventures Fund, L.P., or 7wire LP. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 21:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 21,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017836 · doc4.xml · nonDerivative · entry 6 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,948,484 F11 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire LP, 7wire Ventures, LLC - Series Livongo D and 7wire Ventures, LLC - Series Livongo E. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 21:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 384,629 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017836 · doc4.xml · nonDerivative · entry 5 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,289,261 F9 · kind: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P., or 7wire LP, without consideration to its partners. F10 · ownership.nature: The shares are held of record by 7wire LP. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 21:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 80,099 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017836 · doc4.xml · nonDerivative · entry 4 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 260,358 F7 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F8 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 21:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 72,337 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017836 · doc4.xml · nonDerivative · entry 3 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 235,134 F5 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F6 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 21:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 45,017 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017836 · doc4.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 146,324 F3 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F4 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 21:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 486,183 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017836 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,580,122 F1 · kind: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F2 · ownership.nature: The shares are held of record by 7wire Ventures LLC-Series EosHealth. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Ventures LLC-Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 26, 2020 Filed May 28, 2020 18:00 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 3,966 | $55.00 | $218,130.00 |
DisclosureSEC source: 0001209191-20-032696 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,926,917 F1 · shares: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| May 18, 2020 Filed May 18, 2020 18:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 1,322 | $59.03 | $78,037.66 |
DisclosureSEC source: 0001209191-20-030239 · doc4.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930,883 F2 · shares: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs. Read SEC document |
| May 14, 2020 Filed May 18, 2020 18:55 UTC | Livongo Health, Inc. LVGO · Entity 145566 | GrantCommon Stock | 69,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030239 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,932,205 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 16 equal quarterly installments beginning on August 25, 2020. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 16:46 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 1,322 | $37.86 | $50,050.92 |
DisclosureSEC source: 0001209191-20-025281 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,863,182 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 16,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 9 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,864,504 F12 · kind: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire LP, 7wire Ventures, LLC - Series Livongo D and 7wire Ventures, LLC - Series Livongo E. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 288,469 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 8 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,673,890 F11 · kind: Represents a pro rata in-kind distribution by 7wire LP without consideration to its partners. F10 · ownership.nature: The shares are held of record by 7wire LP. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 802,458 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 7 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,962,359 F9 · kind: Represents the receipt of shares by 7wire LP pursuant to pro rata in-kind distributions by 7wire Ventures, LLC - Series EosHealth and 7wire Ventures LLC - Series Livongo C without consideration to its partners (including 7wire LP). F10 · ownership.nature: The shares are held of record by 7wire LP. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 60,071 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 6 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 340,457 F7 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F8 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 54,247 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 5 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 307,471 F5 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F6 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.